PureTech Health

PRTC

Market cap $452M

PureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

BOSTON--(BUSINESS WIRE)--PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference.

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announces that the Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO), and as a member of the Board of Directors, effective immediately. Robert Lyne commented: “I'm honored to lead PureTech as CEO at such an important moment in its evolution. Over.

PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) shares rose 4.9% to 128p on Wednesday after the company said it had completed a successful end-of-Phase 2 meeting with the US Food and Drug Administration for deupirfenidone, its lead idiopathic pulmonary fibrosis candidate. The regulator's feedback supports advancement into a pivotal Phase 3 trial and confirms the suitability of the streamlined 505(b)(2) regulatory pathway, reducing a major point of uncertainty around the programme.

BOSTON--(BUSINESS WIRE)--PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis.

BOSTON--(BUSINESS WIRE)--PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data for LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia.

BOSTON--(BUSINESS WIRE)--PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with IPF.

BOSTON--(BUSINESS WIRE)--PureTech Presents New Data from Deupirfenidone Phase 2b Open-Label Extension, Further Supporting Potential to Serve as New Standard of Care in IPF.

PureTech Health (PRTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PureTech Health plc (NASDAQ:PRTC ) Q2 2025 Earnings Call August 28, 2025 9:00 AM ET Company Participants Allison Mead Talbot - Senior VP of Communications & Head of Investor Relations Eric Elenko - Co-Founder & President Luba Greenwood - Corporate Participant Robert Lyne - Interim Chief Executive Officer Sven Dethlefs - Corporate Participant Conference Call Participants Heidi Danielle Jacobson - Leerink Partners LLC, Research Division Miles Dixon - Peel Hunt LLP, Research Division Operator Hello, everyone, and thank you for joining the PureTech Health 2025 Half Year Earnings Webcast. My name is Sami, and I'll be coordinating your call today.